Boeing Jumps, Janux Therapeutics Plunges, Signet Slides

- Boeing (BA) shares advanced as much as 9.2% after Malave’s comments, which provided the first detailed look at the planemaker’s cash projections for 2026. The company expects to generate cash again in 2026, with positive free cash flow to reach the “low-single digits” billions of dollars. They still expect to eventually reach the $10 billion cash-generation target outlined by the previous management team, according to Boeing Chief Financial Officer Jay Malave.

- Janux Therapeutics (JANX) shares plunge 41% in premarket trading, after the drug developer gave interim data from an early-stage trial of its experimental therapy for an advanced form of prostate cancer that disappointed Wall Street. Analysts note a decline in the efficacy profile of the drug.

-Signet (SIG) shares slide 4.1% ahead of the bell after the jewelery retailer’s 4Q same-store sales forecast fell short of the consensus estimate. COO Joan Hilson blamed the “measured” 4Q outlook on “external disruptions since late October and potential continued softness in consumer confidence.”

See omnystudio.com/listener for privacy information.